World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Lilly Said to Be Near $1.4 Billion U.S. Settlement
Keywords:
Tags:
The use of Zyprexa in nursing homes, and Lilly's marketing of the drug as "requiring fewer skilled nursing staff hours", and "reduced caregiver stress." The lawsuit alleged that this meant it was " an effective chemical restraint for demanding, vulnerable and needy patients." Zyprexa has the risk of life-threatening infections like pneumonia and of heart failure in elderly patients. Lilly also marketed the use of Zyprexa to treat disruptive children, even though there are side effects of severe weight gain and metabolic disorders. The case is being prosecuted by the US Attorney's Office of the Eastern District of Pennsylvania. In the negotiations Lilly agreed to pay $1.2 billion to 31,000 Zyorexa plaintiffs. This is the biggest case and settlement of its kind.
Eli Lilly & Company.
12/11/2008
Grouped Articles
Putting Eli Lilly’s Biotech Bounce to the Test
Wall Street Journal 07/20/2015
Lilly Warns of Loss From Charges
Wall Street Journal 12/11/2008
Lilly Taps Contractors to Revive Pipeline
Wall Street Journal 01/05/2010
Lilly Ends Work on Alzheimer Treatment
Wall Street Journal 08/18/2010
Drug Maker Agrees to Withdraw Pain Pills From Market
Wall Street Journal 11/20/2010
Lilly Shows Pharma Dividend Trap
Wall Street Journal 01/07/2011
Eli Lilly performance
01/31/2008
Grouped Articles
Lilly Plans to Lay Off 30% of Its Sales Reps
Wall Street Journal 04/12/2013
Eli Lilly's Drug Assembly Line
BusinessWeek 02/25/2010
Eli Lilly Enters Unusual Patent Dispute
Wall Street Journal 08/18/2013
Rivals Threaten to Crowd Out Novo in Expanding Diabetes Market
Wall Street Journal 08/25/2013
Eli Lilly, Unlike Rivals, Isn't Pulling Back on R&D
Wall Street Journal 10/21/2013
Lilly Diabetes Drug Ruled Comparable to Market Leader
Wall Street Journal 02/25/2014
Eli Lilly legal settlements
01/31/2008
Grouped Articles
Eli Lilly Enters Unusual Patent Dispute
Wall Street Journal 08/18/2013
Lilly Said to Be Near $1.4 Billion U.S. Settlement
New York Times 01/15/2009
Lilly Considers $1 Billion Fine to Settle Case
New York Times 01/31/2008
Safety and marketing issues raised about drugs generating large sales for pharmaceutical companies.
10/25/2006
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
Medical Journal Spikes Article On Industry Ties Of Kidney Group - WSJ.com
Wall Street Journal 12/26/2006
Amgen's Star Fades Amid Safety Questions
Wall Street Journal 04/10/2007
Suit Details How J&J Pushed Sales of Procrit
Wall Street Journal 05/10/2007
BusinessWeek 05/21/2007
Sequel for Vioxx Critic: Attack on Diabetes Pill
Wall Street Journal 05/22/2007
Eli Lilly management
01/15/2009
Grouped Articles
Eli Lilly's Drug Assembly Line
BusinessWeek 02/25/2010
Eli Lilly Enters Unusual Patent Dispute
Wall Street Journal 08/18/2013
Lilly Joins With Chinese Biotech to Develop, Market Cancer Drugs
Wall Street Journal 03/20/2015
An ObamaCare Drug Preview in Germany
Wall Street Journal 07/08/2011
Eli Lilly Explores Partnership
Wall Street Journal 09/02/2011
Olympus Coverup Spooks InvestorsB1
Wall Street Journal 11/09/2011
Eli Lilly strategies
01/15/2009
Grouped Articles
Lilly Plans to Lay Off 30% of Its Sales Reps
Wall Street Journal 04/12/2013
Eli Lilly's Drug Assembly Line
BusinessWeek 02/25/2010
Eli Lilly Enters Unusual Patent Dispute
Wall Street Journal 08/18/2013
Rivals Threaten to Crowd Out Novo in Expanding Diabetes Market
Wall Street Journal 08/25/2013
Eli Lilly, Unlike Rivals, Isn't Pulling Back on R&D
Wall Street Journal 10/21/2013
Eli Lilly Sets Plans for Emerging Markets
Wall Street Journal 06/08/2010
Large legal settlements in the pharmaceutical industry.
10/25/2006
The settlements also involve drug pricing and marketing.
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
In Guilty Plea, OxyContin Maker to Pay $600 Million
New York Times 05/10/2007
Glaxo Sues Abbott Labs Over AIDS Drug Pricing
Wall Street Journal 11/09/2007
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Drug Industry to Announce Revised Code on Marketing
New York Times 07/10/2008
Drug Approval Is Not a Shield From Lawsuits, Justices Rule
New York Times 03/05/2009
Slimming down marketing and sales at American and European pharmaceutical companies.
10/25/2006
American and European drug companies are slimming down marketing and sales as the old marketing practices are not working, and new strategies are taking their place.
Grouped Articles
Drug Firms Curb Ties to Doctors
Wall Street Journal 12/18/2013
Wall Street Journal 01/16/2007
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
CEO Gambles on a Novartis Makeover
Wall Street Journal 05/20/2008
Drug Industry to Announce Revised Code on Marketing
New York Times 07/10/2008
Wall Street Journal 10/21/2008
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us
